Key Points
- Surrozen director Tim Kutzkey bought 15,100 shares on Jan. 6 at an average price of $19.89 for $300,339, increasing his direct holdings to 989,893 shares (a 1.55% rise).
- Including earlier purchases (315,457 shares on Nov. 13 at $12.65, 5,266 on Dec. 4 at $17.35 and 30,884 on Dec. 5 at $19.54), Kutzkey has spent roughly $5.0 million on recent stock buys, indicating sizable insider accumulation.
- Shares are under pressure (down ~4.6%, 52-week range $5.90–$24.94) and the company reported a large quarterly loss (EPS -$3.61), with mixed analyst ratings but an average target of $32.00.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) Director Tim Kutzkey purchased 15,100 shares of Surrozen stock in a transaction that occurred on Tuesday, January 6th. The stock was bought at an average cost of $19.89 per share, for a total transaction of $300,339.00. Following the purchase, the director directly owned 989,893 shares in the company, valued at $19,688,971.77. This trade represents a 1.55% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Tim Kutzkey also recently made the following trade(s):
- On Friday, December 5th, Tim Kutzkey bought 30,884 shares of Surrozen stock. The stock was purchased at an average price of $19.54 per share, with a total value of $603,473.36.
- On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The shares were bought at an average cost of $17.35 per share, for a total transaction of $91,365.10.
- On Thursday, November 13th, Tim Kutzkey purchased 315,457 shares of Surrozen stock. The stock was bought at an average cost of $12.65 per share, with a total value of $3,990,531.05.
Surrozen Stock Down 4.6%
Shares of SRZN opened at $19.06 on Friday. The stock has a fifty day simple moving average of $17.88 and a two-hundred day simple moving average of $13.47. Surrozen, Inc. has a 52-week low of $5.90 and a 52-week high of $24.94. The company has a market capitalization of $163.34 million, a PE ratio of -0.85 and a beta of 0.58.
Surrozen (NASDAQ:SRZN - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The company had revenue of $0.98 million during the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. As a group, equities analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Lifesci Capital upgraded Surrozen to a "strong-buy" rating in a report on Thursday, November 13th. Wall Street Zen raised shares of Surrozen to a "sell" rating in a report on Friday, November 28th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Surrozen presently has an average rating of "Moderate Buy" and an average target price of $32.00.
Check Out Our Latest Stock Report on SRZN
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Woodline Partners LP bought a new stake in shares of Surrozen in the third quarter worth $621,000. Millennium Management LLC bought a new position in Surrozen in the 3rd quarter valued at approximately $1,414,000. Citadel Advisors LLC boosted its position in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company's stock valued at $179,000 after buying an additional 3,424 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Surrozen during the third quarter worth $889,000. Finally, Acuta Capital Partners LLC grew its position in Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company's stock worth $2,299,000 after acquiring an additional 8,415 shares during the last quarter. Institutional investors and hedge funds own 66.57% of the company's stock.
Surrozen Company Profile
(
Get Free Report)
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
